Posted by Brigham and Women's Hospital December 23, 2015
The names of two dozen pediatric cancer patients from Boston hospitals have been spray-painted on a construction beam that will soon support a new cafeteria at Brigham and Women’s Hospital.
Tucked away on Shattuck Street, facing the windows of Boston Children’s Hospital, the names “Brooklyn,” “Nicholas,” “Kevin,” and many others are spray-painted in bright orange, light blue, pink, and white on a steel beam that will support the new cafeteria at Brigham and Women’s Hospital (BWH), which is undergoing renovation.
The two dozen names belong to pediatric patients from the Dana-Farber Cancer Institute (DFCI), Boston Children’s Hospital, and the Department of Radiation Oncology at Dana-Farber/Brigham and Women’s Cancer Center, including 5-year-old Brooklyn, who was the first patient to have her name spray-painted on the 63-ton beam. After seeing a Facebook post written by Brooklyn’s mother, a family friend working on the construction site was inspired to begin spray-painting the children’s names.
“Seeing Brooklyn’s name on that steel beam is a feeling I will never forget,” says Kerrin Dooley, Brooklyn’s mother. “To me, the beam is a symbol of community, caring, support, strength, and teamwork – all critical aspects in the fight against cancer.”
Posted by Brigham and Women's Hospital December 10, 2015
Recent research says that eating processed meat products, such as hot dogs and bacon, can increase a person’s risk for colorectal cancer.
Eating processed meat products can increase a person’s risk for colorectal cancer, according to a report from the International Agency for Research on Cancer (IARC), the cancer agency of the World Health Organization (WHO). Processed meat is classified as meat that has been salted, cured, fermented, or smoked to add flavor or preserve the meat. These meats include ham, bacon, sausages, corned beef, hot dogs, canned meat, and beef jerky.
In its findings, the IARC also determined that red meat is “probably carcinogenic to humans,” based on “limited evidence.” Red meat consumption was mainly linked to an increased risk for colorectal cancer, but it also had associations with pancreatic cancer or prostate cancer. Red meat includes beef, veal, pork, mutton, lamb, or goat.
Screening mammography is indicated for a woman who has no symptoms, such as a mass in the breast or nipple discharge. The American College of Radiology recommends that asymptomatic women begin screening mammography beginning at age 40, with yearly examinations recommended thereafter.
Digital 3-D mammography, a new advanced imaging technology for detecting breast cancer, offers a clearer, more complete three-dimensional view of a woman’s breast tissue compared with traditional mammography, which creates two-dimensional images. This technology enables radiologists to see tumors when they are very small and differentiate them from abnormalities that look like tumors, but are often overlapping breast tissue. When radiologists are able to identify malignant tumors at an early stage, it usually means that the cancer has been found before it has spread to other parts of the body. Read More »
Posted by Brigham and Women's Hospital October 13, 2015
BWH plastic surgeons are offering new breast reconstruction options that use a patient’s own thigh tissue.
Plastic surgeons at Brigham and Women’s Hospital (BWH) are now offering women several new options for natural breast reconstruction after a mastectomy.
These new autologous (own tissue) procedures – PAP (profunda artery perforator), TUG (transverse upper gracilis), and DUG (diagonal upper gracilis) flap reconstruction – are typically reserved for patients who do not have enough tissue in their abdomen for reconstruction or who have already had abdominal surgery. Each option involves taking a complete flap of tissue – including skin, fat, and its accompanying blood supply – from the patient’s own leg and transferring it to the chest to create a new breast.
Women are increasingly turning to these and other types of autologous reconstruction as alternatives to reconstruction with artificial implants. Chief among the reasons for this trend is that flap procedures give women the opportunity to have a reconstructed breast with a natural look and feel that lasts. Because they’re biologic, soft tissue reconstructions evolve with the patient. As a woman loses weight, gains weight, or ages, the reconstructed breast tends to respond in proportion to the rest of the body.
Posted by Brigham and Women's Hospital September 10, 2015
Dr. Thomas Clancy, surgical oncologist
Cancers of the pancreas and biliary tract are often difficult to diagnose and treat, as there are no established screening tests and often no early warning signs. Because these cancers tend to present when they are more advanced, avoiding delays in initiating treatment is important.
The Pancreas and Biliary Tumor Center at Dana-Farber/ Brigham and Women’s Cancer Center was created to bring together providers from multiple specialties to provide coordinated and timely care for patients with cancers of the pancreas and biliary tract. The Center also provides care for patients with premalignant lesions of the pancreas and biliary tract. These are tumors or masses that are not yet cancers, but may require surgery or careful monitoring.
In this video, Thomas E. Clancy, MD, FACS, Surgical Oncology, and Brian M. Wolpin, MD, MPH, Medical Oncology, review current treatment approaches for patients with pancreatic and biliary cancers and discuss research on new methods to improve diagnosis and treatment of these cancers.
Posted by Brigham and Women's Hospital August 25, 2015
Among women with symptomatic ovarian cancer, BWH researchers determined that the fallopian tube was a starting point in 50 percent of cases.
Angelina Jolie Pitt’s decision to have her ovaries and fallopian tubes removed highlighted concerns about an uncommon but lethal disease – ovarian cancer. About one in every 70 women will get ovarian cancer in their lifetime, versus one in nine women who will develop breast cancer. Although ovarian cancer is less common, the odds of survival for women with the disease are much lower than for those with breast cancer. Of the 22,000 women who develop ovarian cancer each year, nearly two-thirds die from the disease.
Lower survival rates are partly due to the fact that ovarian cancer often is diagnosed much later than other cancers. Currently, there are no screening tests for early detection of ovarian cancer, and symptoms are non-specific and vague. Symptoms may include bloating, abnormal bleeding, or other abdominal symptoms. However, ongoing research at Brigham and Women’s Hospital (BWH) is shedding light on who is at risk for developing ovarian cancer and what steps can be taken to reduce that risk.
The BRIght Futures Prize supports BWH investigators as they work to answer provocative questions or solve vexing problems in medicine. This year’s BRIght Futures Prize finalists– Christopher Fanta, MD, from the Division of Pulmonary and Critical Care Medicine in the BWH Lung Center; Wilfred Ngwa, PhD, from the Department of Radiation Oncology; and William Savage MD, PhD, from the Department of Pathology – are pursuing forward-thinking and inventive research to improve patient care. Each of the three finalists hopes to receive the $100,000 BRIght Futures Prize, which will be awarded at Discover Brigham on Oct. 7, 2015. Discover Brigham, highlights the cutting-edge biomedical investigations of more than 3,000 researchers at Brigham and Women’s Hospital (BWH).
Posted by Brigham and Women's Hospital August 6, 2015
For the twenty-third year in a row, Brigham and Women’s Hospital (BWH) has been named to U.S. News & World Report’s Honor Roll of America’s Best Hospitals, moving up three spots to number six. The Honor Roll highlights just 15 hospitals, out of nearly 5,000 nationwide, for their breadth and depth of clinical excellence.
In today’s post, we’ve gathered a collection of videos highlighting life-giving breakthroughs in our top-ranked clinical specialties.
Christopher P. Crum, MD, Division Chief of Women’s and Perinatal Pathology, discusses ovarian cancer risk and techniques for detecting ovarian cancer at earlier stages of the disease.
The Department of Obstetrics and Gynecology supports women through all the stages of their lives, offering specialized evaluation and treatment for complex women’s health conditions, including gynecologic cancers.
Posted by Brigham and Women's Hospital July 23, 2015
The average age of transplant recipients in the Stem Cell Transplantation Program today has increased to 55 to 60 years of age.
A stem cell transplant is a lifesaving treatment option that provides healthy stem cells for patients with blood cancers and other diseases. In the Stem Cell Transplantation Program at Dana-Farber/Brigham and Women’s Cancer Center, one of the largest such programs in the world, specialists perform more than 550 transplants each year. The Program has grown substantially over the past few decades.
“A lot has changed since we started our program in 1972,” explains Dr. Joseph Antin, Chief and Program Director for the Stem Cell Transplantation Program. “Advances in technology and our increasing understanding of the underlying biology of the diseases that we treat are enabling us to provide this therapy in cases that we never dreamed possible when we began offering stem cell transplantation more than 40 years ago.”
Posted by Brigham and Women's Hospital June 4, 2015
Genetic mutations associated with certain blood cancers can be detected by testing blood or bone marrow samples.
For patients with aggressive types of leukemia and other blood cancers, quickly identifying and starting the right treatment can make all the difference. In a major advance in the care of these patients, physicians at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) have begun using the Rapid Heme Panel, a high-tech genetic test that provides, within a week, an unprecedented amount of critical information to aid the choice of treatment.
In this video, Dr. Jon Aster, Director of Hematopathology at Brigham and Women’s Hospital (BWH) and one of the developers of the Rapid Heme Panel, explains how the test uses blood or bone marrow samples to search for alterations in genes that are frequently associated with leukemias and myeloproliferative disorders – detecting key mutations that determine prognosis and the specific drugs the cancer is most likely to respond to. The Rapid Heme Panel testing is performed at the Center for Advanced Molecular Diagnostics at BWH.